Stay updated with breaking news from Markus Puhlmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) fell 7.2% during mid-day trading on Tuesday . The stock traded as low as 1.42 and last traded at 1.42. 4,018,949 shares traded hands during trading, an increase of 8% from the average session volume of 3,734,385 shares. The stock had previously closed at 1.53. Analyst Upgrades […]
The Dow Jones index closed higher by around 60 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann acquired 280,000 shares of the stock in a transaction on Wednesday, January 24th. The shares were acquired at an average price of 0.50 per share, with a total value of 140,000.00. Following the purchase, the insider now owns 1,375,425 shares in the company, valued […]
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann bought 280,000 shares of the stock in a transaction dated Wednesday, January 24th. The stock was bought at an average price of 0.50 per share, with a total value of 140,000.00. Following the purchase, the insider now owns 1,375,425 shares of the company’s stock, […]
![Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 -January 17, 2024 at 08:03 am EST - Vimarsana News](https://www.marketscreener.com/images/twitter_MS_fdnoir.png)
SEATTLE, Jan. 17, 2024 -- Perspective Therapeutics, Inc. , today announced that it began patient recruitment for the second dosing cohorts in clinical studies for both of its lead product...